Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key Metrics

For the quarter ended September 2024, Amgen (AMGN) reported revenue of $8.5 billion, up 23.2% over the same period last year. EPS came in at $5.58, compared to $4.96 in the year-ago quarter.The reported revenue represents a surprise of -0.04% over the Zacks Consensus Estimate of $8.51 billion. With the consensus EPS estimate being $5.11, the EPS surprise was +9.20%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- EPOGEN- US: $33 million compared to the $34.91 million average estimate based on nine analysts. The reported number represents a change of -34% year over year. Product Sales- Neulasta- US: $84 million versus $81.89 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a -8.7% change. Product Sales- Neulasta- ROW: $26 million compared to the $24.77 million average estimate based on seven analysts. The reported number represents a change of -18.8% year over year. Product Sales- Enbrel- ROW: $8 million versus the six-analyst average estimate of $7.18 million. The reported number represents a year-over-year change of -11.1%. Revenue- Product sales: $8.15 billion versus the 10-analyst average estimate of $8.15 billion. The reported number represents a year-over-year change of +24.5%. Product Sales- Neulasta- Total: $110 million compared to the $105.06 million average estimate based on 10 analysts. The reported number represents a change of -11.3% year over year. Product Sales- Enbrel- Total: $825 million compared to the $920.53 million average estimate based on 10 analysts. The reported number represents a change of -20.3% year over year. Product Sales- BLINCYTO- Total: $327 million versus $277.33 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +48.6% change. Product Sales- Vectibix- Total: $282 million compared to the $263.77 million average estimate based on 10 analysts. The reported number represents a change of +11.9% year over year. Product Sales- KYPROLIS- Total: $378 million versus $382.26 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change. Product Sales- Repatha- Total: $567 million versus the 10-analyst average estimate of $523.99 million. The reported number represents a year-over-year change of +39.7%. Product Sales- Aranesp- Total: $337 million versus the 10-analyst average estimate of $308.99 million. The reported number represents a year-over-year change of +4.3%. View all Key Company Metrics for Amgen here>>>Shares of Amgen have returned -1.4% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks